Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model

BACKGROUND: Triple-negative breast cancer (TNBC) represents an aggressive subtype with limited therapeutic options. Experimental preclinical models that recapitulate their tumors of origin can accelerate target identification, thereby potentially improving therapeutic efficacy. Patient-derived xenog...

Descripción completa

Detalles Bibliográficos
Autores principales: Matossian, Margarite D., Burks, Hope E., Elliott, Steven, Hoang, Van T., Bowles, Annie C., Sabol, Rachel A., Wahba, Bahia, Anbalagan, Muralidharan, Rowan, Brian, Abazeed, Mohamed E., Bunnell, Bruce A., Moroz, Krzysztof, Miele, Lucio, Rhodes, Lyndsay V., Jones, Steven D., Martin, Elizabeth C., Collins-Burow, Bridgette M., Burow, Matthew E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407287/
https://www.ncbi.nlm.nih.gov/pubmed/30845999
http://dx.doi.org/10.1186/s12885-019-5401-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407287/
https://www.ncbi.nlm.nih.gov/pubmed/30845999
http://dx.doi.org/10.1186/s12885-019-5401-2

Ejemplares similares